eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | leukemia, acute myeloid |
| Comorbidity | C0376545|hematological malignancy |
| Sentences | 2 |
| PubMedID- 26028971 | hematological malignancy of acute myeloid leukemia (aml) type is highly heterogeneous with a high incidence of relapse averaging 30%–50% in less than 5 years due to drug resistance, even though 70%–80% patients undergo remission following induction chemotherapy.1–3 inability to clear the entire population of aml cells following drug treatment has been attributed to the microenvironmental cell adhesion-mediated drug-resistance (camdr) cues provided by the bone marrow 3-d structure to aml cells.4 differential interactions of aml cells with neighboring cells or with extracellular matrix (ecm) proteins in the bone marrow microenvironment have been shown to impart camdr to aml cells.5–10 in this crucial scenario, the interaction of very late antigen 4 (vla 4) expressed by aml cells with stromal fibronectin (fn) plays a major role in camdr.1,11 thus, cell adhesion to a 3-d matrix could be effectively exploited to cultivate these drug-resistant cells toward testing different experimental drugs for better therapy. |
| PubMedID- 25664374 | In subgroups according to hematological malignancy, patients with acute myeloid leukemia (aml) had lower cfdna levels than patients with lymphoma. |
Page: 1